Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit

Rhea-AI Summary

Bionoid Pharma (OTC PINK:BINP) has announced the completion of its audited financial statements for fiscal year 2024. The audit was performed by Aloba Awomolo & Partners LLP, Chartered Professional Accountants. CEO Wayne Cockburn highlighted this as a significant milestone for the company, positioning them for their next phase of corporate growth strategy.

The company plans to use this audit completion as a stepping stone toward their application to uplist to a more senior stock exchange. The audited financial statements will be made available on the OTC Markets website, demonstrating the company's commitment to transparency and corporate governance.

Positive

• Successful completion of 2024 financial audit
• Progress toward potential uplisting to senior exchange
• Enhanced financial transparency and governance

Negative

• Currently trading on OTC Pink market, indicating lower tier listing

NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its audited financial statements for the fiscal year ended December 31, 2024. The audit was conducted by Aloba Awomolo & Partners LLP, Chartered Professional Accountants, who were engaged earlier this year as Bionoid's external auditor.

"This marks an important milestone for Bionoid," said Wayne Cockburn, CEO of Bionoid Pharma. "Completing our 2024 audit puts us in a strong position as we now shift our focus toward the next phase of our corporate growth strategy - including the work required to advance our application to uplist to a more senior stock exchange. We remain committed to transparency, strong governance, and delivering long-term value to our shareholders."

The audited financial statements will be filed on https://www.otcmarkets.com/.

About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.

AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.

Stay Connected:

Website:	https://bionoidpharma.com/ https://aimaverickintel.com/
OTC Markets:	BINP
X (formerly Twitter):	@BionoidPharminc

For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com

SOURCE: Bionoid Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the significance of Bionoid Pharma (BINP) completing its 2024 financial audit?

The audit completion is a important milestone that positions BINP for its next growth phase and supports their planned application to uplist to a senior stock exchange.

Which accounting firm conducted Bionoid Pharma's (BINP) 2024 financial audit?

Aloba Awomolo & Partners LLP, Chartered Professional Accountants, conducted BINP's 2024 financial audit.

Where can investors access Bionoid Pharma's (BINP) 2024 audited financial statements?

BINP's 2024 audited financial statements will be available on the OTC Markets website (otcmarkets.com).

What are Bionoid Pharma's (BINP) plans following the 2024 audit completion?

BINP plans to advance their application for uplisting to a more senior stock exchange as part of their corporate growth strategy.